Reports Q1 revenue $15.8B, consensus $15.2B. “Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients,” said Robert Davis, chairman and chief executive officer, Merck. “We drove strong growth across key therapeutic areas, executed strategic business development, and in the U.S., we are now launching WINREVAIR, a significant new product in the cardiometabolic space for adults with pulmonary arterial hypertension, a progressive and debilitating disease. We have important opportunities ahead of us across all areas of our business, and we are highly focused on realizing them.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- MRK Upcoming Earnings Report: What to Expect?
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- Moderna Stock (NASDAQ:MRNA): This mRNA Tech Pioneer Has Rebound Potential
- Merck price target raised to $143 from $140 at Berenberg
- Piper Sandler pharmaceuticals analysts hold an analyst/industry conference call
Questions or Comments about the article? Write to editor@tipranks.com